ribosepharm GmbH
Division of Teva Pharmaceutical Industries Ltd.
www.ribosepharm.com
Latest From ribosepharm GmbH
Specialty Pharma: Tapping Japan
Economic recovery, pharmaceutical consolidation, and a burgeoning private equity sector have encouraged a new cluster of Japan-focused specialty pharmas
Deals Shaping the Medical Industry (2/06)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Cephalon: Can Spec Pharma do R&D?
Cephalon's 2005 dealmaking flurry illustrates the growing influence of in-house R&D on a firm whose success to date has come from in-licensing. Its challenge will be selling investors pipeline potential, as well as earnings growth.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Germany
-
Germany
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
- Contact Info
-
ribosepharm GmbH
Phone: (49) 089 45450 0
Mountain to Laim Rd. 127
Munich, D-81673
Germany
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ribosepharm GmbH
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice